Centene Corporation (BVMF:C1NC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 144.36B -14.9% |
| Revenue (ttm) | 930.31B +16.4% |
| Net Income | -33.62B |
| EPS | -68.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 15.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5 |
| Average Volume | 25 |
| Open | 298.27 |
| Previous Close | 293.33 |
| Day's Range | 298.27 - 298.27 |
| 52-Week Range | 136.80 - 326.10 |
| Beta | 1.06 |
| RSI | 75.28 |
| Earnings Date | Apr 28, 2026 |
About Centene
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and servi... [Read more]
News
Centene upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Centene (CNC) to Buy from Hold with a price target of $80, up from $53. The firm upgraded three managed care names citing a stabilizing managed care…
Centene price target raised to $58 from $50 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Centene (CNC) to $58 from $50 and keeps a Neutral rating on the shares. The firm views the Q1 reports…
Centene upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Centene (CNC) to Buy from Hold with an $80 price target
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
Superior HealthPlan Awards $100,000 in Grants to 10 Community-based Organizations in Texas
The funding is made available through an annual program that addresses barriers to healthcare. AUSTIN, Texas, May 12, 2026 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care orga...
Health Insurers Performing Better But There's Potential Trouble Ahead
Health insurance companies including UnitedHealthcare, CVS Health's Aetna, Centene and Blue Cross and Blue Shield plans owned by Elevance Health are seeing lower costs from patients submitting claims.
Centene price target raised to $48 from $38 at TD Cowen
TD Cowen raised the firm’s price target on Centene (CNC) to $48 from $38 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
Centene price target raised to $46 from $37 at Baird
Baird analyst MichaThe firm updated its model following Q1 resultsel Ha raised the firm’s price target on Centene (CNC) to $46 from $37 and keeps a Neutral rating on the…
Early notable gainers among liquid option names on April 29th
Notable gainers among liquid option names this morning include NXP Semiconductors (NXPI) $286.23 +55.84, Seagate (STX) $675.55 +96.52, Generac (GNRC) $242.79 +25.67, Western Digital (WDC) $429.35 +38....
Centene price target raised to $55 from $42 at UBS
UBS raised the firm’s price target on Centene (CNC) to $55 from $42 and keeps a Neutral rating on the shares. Centene’s prudent approach to guidance suggests further upside is…
Centene price target raised to $58 from $49 at Truist
Truist raised the firm’s price target on Centene (CNC) to $58 from $49 and keeps a Buy rating on the shares after its Q1 earnings beat. The company’s cash flow…
Centene price target raised to $40 from $32 at Goldman Sachs
Goldman Sachs analyst Scott Fidel raised the firm’s price target on Centene (CNC) to $40 from $32 and keeps a Sell rating on the shares. Centene rallied after a Q1…
Centene price target raised to $58 from $45 at Oppenheimer
Oppenheimer raised the firm’s price target on Centene (CNC) to $58 from $45 and keeps an Outperform rating on the shares. The firm says Centene’s Q1 results provided a very…
Centene double upgraded to Buy from Underperform at BofA
As previously reported, BofA double upgraded Centene (CNC) to Buy from Underperform with a price target of $60, up from $34, due to Medicaid margins likely bottoming in 2026. The…
Centene upgraded to Buy from Underperform at BofA
BofA upgraded Centene (CNC) to Buy from Underperform with a price target of $60, up from $34.
Centene price target raised to $63 from $54 at Barclays
Barclays raised the firm’s price target on Centene (CNC) to $63 from $54 and keeps an Overweight rating on the shares. The company’s Q1 results underscore its conservative guidance assumptions…
Cantor upgrades Centene to Overweight on margin improvement path
Cantor Fitzgerald analyst Sarah James last night upgraded Centene (CNC) to Overweight from Neutral with a price target of $60, up from $41. The company’s path to margin improvement “has…
Centene upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Centene (CNC) to Overweight from Neutral with a $60 price target
Centene stock rises as earnings beat, outlook lifted on cost cuts
Shares of Centene Corporation rose about 14% on Tuesday after the company reported stronger-than-expected first-quarter results, driven by cost controls and steady premium growth. The St. Louis-based ...
Centene Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong EPS and revenue growth, driven by Medicaid and Medicare outperformance and disciplined cost management. Full-year EPS guidance was raised, with Marketplace margins conservatively set pending further risk adjustment data.
Centene Quarterly report: Q1 2026
Centene has published its Q1 2026 quarterly earnings report on April 28, 2026.
Centene Earnings release: Q1 2026
Centene released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Centene's Obamacare Enrollment Drops By 2 Million After Congress Strips Subsidies
Health insurer Centene reported first quarter net income of more than $1.5 billion despite a drop of 2 million enrollees in individual coverage under the Affordable Care Act also known as Obamacare.